In the Claims:

The following listing of claims will replace any/all prior versions, and listings, of claims in the application:

Claim **1** (Currently Amended) A method of treating an individual suffering from incontinence, the method comprising the step of administering to the individual a therapeutically effective amount of a composition comprising ~~a compound having a pharmacological selectivity of serotonin (K_i)/norepinephrine (K_i) of at least about 5000~~ optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof.

Claim **2** (Currently Amended) The method of claim **1** wherein said ~~composition~~ optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.1 to about 10 mg/day.

Claim **3** (Currently Amended) The method of claim **2** wherein said ~~composition~~ optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 8 mg/day.

Claim **4** (Currently Amended) The method of claim **3** wherein said ~~composition~~ optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 5 mg/day.

Claim **5** (Currently Amended) The method of claim **4** wherein said ~~composition~~ optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 2.5 mg/day.

Claim **6** (Currently Amended) The method of claim **5** wherein said ~~composition~~ optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 0.9 mg/day.

Claim **7** (Currently Amended) The method of claim **6** wherein said ~~composition~~ optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 0.8 mg/day.

Claim **8** (Currently Amended) The method of claim **7** wherein said ~~composition~~ optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 0.75 mg/day.

Claim **9** (Original) The method of claim **1** wherein said composition is administered orally, topically, parenterally, transdermally, rectally, or vaginally.

Claim **10** (Original) The method of claim **9** wherein said composition is orally administered, and further comprising a pharmaceutically acceptable carrier selected from the

group consisting of a binder, diluent, lubricant, disintegrating agent, effervescing agent, dyestuff, sweetener, wetting agent, and mixtures thereof.

Claim **11** (Original) The method of claim **10** wherein the oral administration is by a sachet, capsule, tablet, or aerosol spray.

Claim **12** (Currently Amended) The method of claim **9** wherein said composition is parenterally administered subcutaneously, ~~intraveously~~ intravenously, or intramuscularly.

Claim **13** (Canceled).

Claim **14** (Currently Amended) The method of claim ~~13~~ **1** wherein the pharmaceutically acceptable salt is a methanesulfonate salt.

Claim **15** (Currently Amended) The method of claim ~~13~~ **1** wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 90 wt.% of (S,S) reboxetine, and less than about 10 wt.% of (R,R) reboxetine, based on the total weight of ~~the (S,S) and (R,R)~~ reboxetine present.

Claim **16** (Currently Amended) The method of claim **15** wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 97 wt.% of (S,S) reboxetine and less than about 3 wt.% of (R,R) reboxetine, based on the total weight of ~~the (S,S) and (R,R)~~ reboxetine present.

Claim **17** (Currently Amended) The method of claim **16** wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 99 wt.% of (S,S) reboxetine and less than about 1 wt.% of (R,R) reboxetine, based on the total weight of ~~the (S,S) and (R,R)~~ reboxetine present.

Claims **18-38** (Canceled).

Claim **39** (Currently Amended) A method of treating incontinence in an individual while diminishing adverse side effects, the method comprising the step of administering to the individual a total dose of about 0.1 to about 10 mg/day of an optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof~~, said optically pure (S,S) reboxetine being substantially free of (R,R) reboxetine~~.

Claim **40** (Original) The method of claim **39** wherein said adverse side effects comprise dizziness, insomnia, lightheadedness, changes in blood pressure, sweating, gastrointestinal disturbances, sexual dysfunction in males, anticholinergic-like effects, and side effects with drug-drug interactions.

Claims **41-53** (Canceled).

Claim **54** (Previously Presented) The method of claim **1**, wherein incontinence is selected from the group consisting of stress incontinence, genuine stress incontinence, and mixed incontinence.

Claim **55** (Canceled).

Claim **56** (Previously Presented)The method of claim **39**, wherein incontinence is selected from the group consisting of stress incontinence, genuine stress incontinence, and mixed incontinence.

Claim **57** (Canceled).

Claim **58** (New) The method of claim **39**, wherein said optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 8 mg/day.

Claim **59** (New) The method of claim **58**, wherein said optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 5 mg/day.

Claim **60** (New) The method of claim **59**, wherein said optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 2.5 mg/day.

Claim **61** (New) The method of claim **60**, wherein said optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 0.9 mg/day.

Claim **62** (New) The method of claim **61**, wherein said optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 0.8 mg/day.

Claim **63** (New) The method of claim **62**, wherein said optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 0.75 mg/day.

Claim **64** (New) The method of claim **39**, wherein said composition is administered orally, topically, parenterally, transdermally, rectally, or vaginally.

Claim **65** (New) The method of claim **64**, wherein said composition is orally administered, and further comprising a pharmaceutically acceptable carrier selected from the group consisting of a binder, diluent, lubricant, disintegrating agent, effervescing agent, dyestuff, sweetener, wetting agent, and mixtures thereof.

Claim **66** (New) The method of claim **65**, wherein the oral administration is by a sachet, capsule, tablet, or aerosol spray.

Claim **67** (New) The method of claim **64**, wherein said composition is parenterally administered subcutaneously, intravenously, or intramuscularly.

Claim **68** (New) The method of claim **39**, wherein the pharmaceutically acceptable salt is a methanesulfonate salt.

Claim **69** (New) The method of claim **39**, wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 90 wt. % of (S,S) reboxetine, and less than about 10 wt. % of (R,R) reboxetine, based on the total weight of reboxetine present.

Claim **70** (New) The method of claim **69**, wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 97 wt. % of (S,S) reboxetine and less than about 3 wt. % of (R,R) reboxetine, based on the total weight of reboxetine present.

Claim **71** (New) The method of claim **70**, wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 99 wt. % of (S,S) reboxetine and less than about 1 wt. % of (R,R) reboxetine, based on the total weight of reboxetine present.